THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.
Key facts
| Status | Awarded |
|---|---|
| Estimated value | $145,378,689.01 |
| Submission deadline | Deadline not published |
| Published | Sep 26, 2019 |
| Buyer | Office of Assistant Secretary for Preparedness and Response |
| Country | United States · DC |
| CPV code | NAICS 541714 (RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTEC) · PSC AN73 |
| Source | USAspending.gov Federal Contract Awards ↗ |
- Status
- Awarded
- Estimated value
- $145,378,689.01
- Submission deadline
- Deadline not published
- Published
- Sep 26, 2019
- Country
- United States
- CPV code
- NAICS 541714 (RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTEC) · PSC AN73
- Source
- USAspending.gov Federal Contract Awards
Contract outcome & evergreen alternatives
This notice is no longer open for submissions. The original remains available for reference.
| Awarded supplier / winner | Registration / LEI number | Country | Awarded contract amount | Award date |
|---|---|---|---|---|
| ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) | US-UEI: H5E8NU6N2HZ5 | United States | $145,378,689.01 | Sep 26, 2019 |
Checked:
The original notice takes precedence. Its status and conditions can change after collection.
Description
THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.
Awarding Agency: Department of Health and Human Services — Office of Assistant Secretary for Preparedness and Response.
NAICS 541714: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY).
PSC AN73: R&D- MEDICAL: SPECIALIZED MEDICAL SERVICES (ADVANCED DEVELOPMENT).
Period of Performance: 2019-09-26 to 2027-09-30.